GoodRx Q3 revenue $180M; adjusted revenue $190M, net loss $38.5M

GoodRx Holdings, Inc.

2023-Q3 EPS reported $0.04 revenue$553,621,000

Revenue of $180.0M, reduced by $10M client contract termination; adjusted revenue $190.0M.
Net loss $38.5M (21.4% margin); adjusted net income $25.5M (13.4% margin).
Adjusted EBITDA $53.5M (28.1% margin); operating cash flow $60.3M.
Over 550K prescribers via Provider Mode; >7M consumers of prescription offerings.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

GoodRx Holdings, Inc. reported financial results for three and nine months ended September 30, 2023.

Period: three and nine months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, GoodRx Holdings, Inc. (the “Company”) announced the Company’s financial results for the three and nine months ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001809519-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.